SEC Form 4 · accession 0001209191-15-087442
Bone Biologics Corp · BBLG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deina H Walsh
Officer — Chief Financial Officer
Period of report
Dec 28, 2015
Accepted (ET)
Dec 30, 2015 · 8:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419554
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $1.59 | Dec 28, 2015 | A | 239,825 | A | — | Dec 27, 2025 | Common Stock | 239,825 | 239,825 | D |
| Employee Stock Option (Right to Buy)F2 | $1.59 | Dec 28, 2015 | A | 465,795 | A | — | Dec 27, 2025 | Common Stock | 465,795 | 465,795 | D |
Explanation of responses
- F1159,883 shares subject to the option are immediately exercisable and the remaining shares subject to the option shall vest and become exercisable on November 4, 2016, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2015 Equity Incentive Plan (the "Plan")) on such vesting date.
- F21/3 of the shares subject to the option shall vest and become exercisable on each of December 1, 2016, December 1, 2017 and December 1, 2018, subject to the Reporting Person's Continuous Service (as defined in the Plan) on each such vesting date.